Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exebacase for Staphylococcus aureus Bacteremia and Endocarditis
NCT04160468Phase 3Terminated
- Sponsor
- ContraFect Corporation
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of exebacase in Staphylococcus aureus bacteremia (SAB), infective endocarditis (IE), sponsored by ContraFect Corporation. Started Dec 2019; status: terminated.
02
Drugs
exebacase
03
Conditions
Staphylococcus aureus bacteremia (SAB)infective endocarditis (IE)
Beyond the preview
Go deeper on NCT04160468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160468.